Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments

Neuropsychopharmacology

Volumn 22, Issue 4, 2000, Pages 346-356

  Haddjeri, Nasser ^a   Szabo, Steven T ^a   De Montigny, Claude ^a   Blier, Pierre ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Dorsal hippocampus; Imipramine; Lithium; Paroxetine; Tranylcypromine; WAY 100635, 5 HT(1A) receptors

Indexed keywords

IMIPRAMINE; LITHIUM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; ELECTROPHYSIOLOGY; FOREBRAIN; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FREE RADICAL SCAVENGERS; HIPPOCAMPUS; IMIPRAMINE; LITHIUM; MALE; MONOAMINE OXIDASE INHIBITORS; PAROXETINE; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; TRANYLCYPROMINE;

EID: 0033953677     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00138-4     Document Type: Article

References (72)

1. Baptista T.J., Hernandez L., Burguera J.L., Burguera M., Hoebel B.G. Chronic lithium administration enhances serotonin release in the lateral hypothalamus but not in the hippocampus. A microdialysis study. J Neural Trans. 82:1990;31-41.
2. Beck S.G. 5-Hydroxytryptamine increases excitability of CA1 hippocampal pyramidal cells. Synapse. 10:1992;334-340.
3. 7 receptor mediated inhibition of sAHP in CA3 hippocampal pyramidal cells. Soc Neurosci Abst 24:435.4.
4. Bel N., Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei. An in vivo microdialysis study Eur J Pharmacol. 229:1992;101-103.
5. Besson A, Haddjeri N, Debonnel G, Blier P, de Montigny C (1997): Effects of the combination of mirtapine and paroxetine on the 5-HT neurotransmission. Soc Neurosci Abst 23:485.3.
6. Bitsch Jensen J., Mørk A. Altered protein phosphorylation in the rat brain following chronic lithium and cabamazepine treatments. Eur Neuropsychopharmacol. 7:1997;173-179.
7. Blier P., Bouchard C. Modulation of 5-HT release in guinea pig brain following long-term administration of antidepressant drugs. Brit J Pharmacol. 113:1994;485-495.
8. Blier P., de Montigny C. Short-term lithium administration enhances serotonergic neurotransmission. Electrophysiological evidence in the rat CNS Eur J Pharmacol. 113:1985;69-77.
9. Blier P., de Montigny C., Azzaro A.J. Modification of serotoninergic and noradrenergic neurotransmission by repeated administration of monoamine oxidase inhibitors. Electrophysiological studies in the rat central nervous system J Pharmacol Exp Ther. 237:1986;987-994.
10. 1A agonist gepirone. Electrophysiological studies in the rat brain Synapse. 1:1987;470-480.
11. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 15:1994;220-225.
12. 1A receptors without altering 5-HT autoreceptor sensitivity. An electrophysiological study in the rat brain Synapse. 1:1987;225-232.
13. 1A receptors in dorsal raphe and hipocampus. I. Effect of spiperone J Pharmacol Exp Ther. 265:1993;7-15.
14. Chaput Y., de Montigny C. Effects of the 5-HT1 receptor antagonist BMY 7378 on the 5-HT neurotransmission. Electrophysiological studies in the rat central nervous system J Pharmacol Exp Ther. 246:1988;359-370.
15. Chaput Y., de Montigny C., Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors. Electrophysiological studies in the rat brain Naunyn-Schmiedeberg's Arch Pharmacol. 33:1986;342-348.
16. Chaput Y., de Montigny C., Blier P. Presynpatic and postsynaptic modifications of the serotonin system by long-term antidepressant treatments. Electrophysiological studies in the rat brain Neuropsychopharmacology. 5:1991;219-229.
17. Cummings J.L. The neuroanatomy of depression. J Clin Psychiat. 543:1993;14-20.
18. de Montigny C. Electroconvulsive treatments enhance responsiveness of forebrain neurons to serotonin. J Pharmacol Exp Ther. 228:1984;230-234.
19. de Montigny C., Aghajanian G.K. Tricyclic antidepressants. Long-term treatment increases responsivity of rat forebrain neurons to serotonin Science. 202:1978;1303-1306.
20. de Montigny C., Grunberg F., Mayer A., Deschesne J.P. Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders. Brit J Psychiat. 138:1981;252-256.
21. de Montigny C., Cournoyer G., Morissette R., Langlois R., Caille G. Lithium carbonate addition to tricyclic antidepressant-resistant depression. Correlations with neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiat. 40:1983;1327-1334.
22. Dixon J.F., Hokin L.E. The antibipolar drug valproate mimics lithium in stimulation glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and biphosphates. Proc Natl Acad Sci USA. 94:1997;4757-4760.
23. Dixon J.F., Hokin L.E. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA. 95:1998;8363-8368.
24. Dixon J.F., Los G.V., Hokin L.E. Lithium stimulates glutamate release and inositol 1,4,5-trisphosphate accumulation via activation of N-methyl-D-aspartate receptor in monkey and mouse cortex slices. Proc Natl Acad Sci USA. 91:1994;8358-8362.
25. Ferrer A., Artigas P. Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain. Eur J Pharmacol. 263:1994;227-234.
26. Fletcher A., Forster E.A., Bill D.J., Brown G., Cliffe I.A., Hartley J.E., Jones D.E., McLenachan A., Stanhope K.J., Critchley D.J., Childs K.J., Middlefell V.C., Lanfumey L., Corradetti R., Laporte A.M., Gozlan H., Hamon M., Dourish C.T. Electrophysiological, biochemical, neurohormonal, and behavioral studies with WAY-100635, a potent, selective, and silent 5-HT1A receptor antagonist. Behav Brain Res. 73:1996;337-353.
27. Fornal C.A., Metzler C.W., Gallegos R.A., Veasey S.C., McCreary A.C., Jacobs B.L. WAY 100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats. Comparison with (S)-WAY-100135 J Pharmacol Exp Ther. 278:1996;752-762.
28. 1A receptor antagonist, WAY 100635. Eur J Pharmacol. 281:1995;81-88.
29. 1Areceptors antagonist and an SSRI in vivo. Effects on 5-HT cell firing and extracellular 5-HT Brit J Pharmacol. 115:1995;1064-1070.
30. Goodnough DB, Baker GB (1994) Comparisons of the actions of high and low doses of the MAO inhibitor tranycylpromine on 5-HT2 binding sites in the rat cortex. J Neural Transm 41:127-134.
31. 1A receptor function. Prog Neuro-Psychopharmacol Biol Psychiat. 13:1989;445-451.
32. 1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat. Evidence for a postsynaptic mechanism Psychopharmacology. 90:1986;488-493.
33. Grahame-Smith D.G., Green A.R. The role of brain 5-hydroxytryptamine in the hyperactivity produced by lithium and monoamine oxidase. Brit J Pharmacol. 52:1974;19-26.
34. 2-adrenoreceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn-Schmiedeberg's Arch Pharmacol. 355:1997;20-29.
35. 1A receptors. J Neurosci. 19:1998;10150-10156. a.
36. Haddjeri N., de Montigny C., Curet O., Blier P. Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-HT neurotransmission. Eur J Pharmacol. 343:1998;179-192. b.
37. Heninger GR, Charney DS (1987): Mechanisms of action of antidepressant treatments: Implications for the etiology and treatment of depression disorders. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress. New York: Raven, pp 535-544.
38. Hotta I., Yamawaki S. Possible involvement of presynaptic 5-HT autoreceptors in effect of lithium on 5-HT release in hippocampus of rat. Neuropharmacology. 27:1988;987-992.
39. Jope R.S., Williams M.B. Lithium and brain signal transduction systems. Biochem Pharmacol. 47:1994;429-441.
40. Kandel E.R., Spencer W.A. Electrophysiology of hippocampal neurons. II. After-potentials and repetitive firing. J Neurophysiol. 24:1961;243-259.
41. Karoum F., Korpi E.R., Chuang L.W., Linnoila M., Wyatt R.J. The effects of desipramine, zimelidine, electroconvulsive treatment, and lithium on rat brain biogenic amines. Comparison with peripheral changes Eur J pharmacol. 121:1986;377-385.
42. 1A receptor antagonist, to the rat. J Neurochem. 64:1994;2716-2726.
43. Lambert P.D., McGirr K.M., Ely T.D., Kilts C.D., Kuhar M.J. Chronic lithium treatment decreases neuronal activity in the nucleus accumbens and cingulate cortex of the rat. Neuropsychopharmacology. 21:1999;229-237.
44. Lejeune F., Millan M.J. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors- WAY 100,635-reversible actions of the highly selective ligands, flesinoxan, and S 15535. Synapse. 30:1998;172-180.
45. Lenox R.H., McNamara R.K., Papke R.L., Manji H.K. Neurobiology of lithium. An update J Clin Psychiat. 59:1998;37-47.
46. Maes M, Meltzer HY (1995): The serotonin hypothesis of major depression. In Bloom FE, Kupfer DJ (ed), Psychopharmacology: The Fourth Generation of Progress. New York: Raven, pp 933-944.
47. Manji H.K., Potter W.Z., Lenox R.H. Signal transducing pathways. Molecular targets for lithium's actions. Arch Gen Psychiat. 52:1995;531-543.
48. Menkes D.B., Aghajanian G.K., McCall R.B. Chronic antidepressant treatment enhances α-adrenergic and serotonergic responses in the facial nucleus. Life Sci. 27:1980;45-55.
49. Minegishi A., Fukumori R., Satoh T., Kitagawa H., Yanaura S. Interaction of lithium and disulfiram in hexobarbital hypnosis. Possible role of the 5-HT system J Pharmacol Exp Ther. 218:1981;481-487.
50. Mørk A. Actions of lithium on the cyclic AMP signaling system in various regions of the brain. Possible relations to its psychotropic actions. A study on the adenylate cyclase in rat cerebral cortex, corpus striatum, and hippocampus Pharmacol Toxicol. 73:1993;1-47.
51. Mørk A., Geisler A. Effects of chronic lithium treatment on agonist-enhanced extracellular concentrations of cyclic AMP in the dorsal hippocampus of freely moving rats. J Neurochem. 65:1995;134-139.
52. 2-adrenoreceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology. 10:1994;41-51.
53. Newman M.E., Drummer D., Lerer B. Single and combined effects of desipramine and lithium on serotonergic receptor number and second messenger function in rat brain. J Pharmaco Exp Ther. 252:1990;826-831.
54. Nowak G., Dulinski J. Effect of repeated treatment with electroconvulsive shock (ECS) on serotonin receptor density and turnover in the rat cerebral cortex. Pharmacol Biochem Behav. 38:1991;691-694.
55. Okamoto Y., Motohashi N., Hayaakawa H., Muraoka M., Yamawaki S. Addition of lithium to chronic antidepressant treatment potentiates presynaptic serotonergic function without changes in serotonergic receptors in the rat cerebral cortex. Neuropsychobiology. 33:1996;17-20.
56. Pei Q., Leslie R.A., Grahame-Smith D.G., Zetterstrom T.R.C. 5-HT efflux from rat hippocampus in vivo produced by 4-aminopyridine is increased by chronic lithium administration. NeuroReport. 6:1995;716-720.
57. Piñeyro G., Blier P., de Montigny C. Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci. 14:1994;3036-3047.
58. Price L.H., Charney D.S., Delgado P.L. Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drug. J Clin Psychiat. 51:1990;44-50. a.
59. Price L.H., Charney D.S., Delgado P.L., Heninger G.R. Lithium and serotonin function. Implications for the serotonin hypothesis of depression Psychopharmacology. 100:1990;3-12. b.
60. Rouillon F., Gorwood P. The use of lithium to augment antidepressant medication. J Clin Psychiat. 59:1998;32-39.
61. Rutter J.J., Gundlah C., Auerbach S.B. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Let. 171:1994;183-186.
62. Sangdee C., Franz D.N. Lithium enhancement of 5-HT transmission induced by 5-HT precursors. Biol Psychiat. 15:1980;59-75.
63. Sharp T., Bramwell S.R., Lambert P., Grahame-Smith D.G. Effect of short- and long-term administration of lithium on the release of endogenous 5-HT in the rat hippocampus of the rat in vivo and in vitro. Neuropharmacology. 30:1991;977-984.
64. 1A receptor binding and receptor-mediated hypothermia in the rat. Neuropharmacology. 31:1992;1089-1094.
65. Susuki T., Kasamo K., Ueda K., Kojima T. Endogenous 5-HT tonically suppresses firing activity of dorsal hippocampus CA1 pyramidal neurons in quiet awake rats. In vivo electrophysiological evidence Soc Neurosci Abts. 25:1999;174-177.
66. Torres G.E., Arfken C.L., Andrade R. 5-Hydroxytryptamine4 receptors reduce afterhyperpolarization in hippocampus by inhibiting calcium-induced calcium release. Mol Pharmacol. 50:1996;1316-1322.
67. Treiser S.L., Cascio C.S., O'Donuhue T.L., Keller Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science. 213:1981;1529-1531.
68. Van Praag H.M., Asnis G.M., Khan R.S. Monoamines and abnormal behavior. A multiaminergic perspective Brit J Psychiat. 157:1990;723-734.
69. Wang RY, Aghajanian GK (1980) Enhanced sensitivity of amigdaloid neurons to serotonin and norepinephrine by antidepressant treatments. Commun Psychopharmacol 4:83-90.
70. Wang H.-Y., Friedman E. Chronic lithium. Desensitization of autoreceptors mediating 5-HT release Psychopharmacology. 94:1988;312-314.
71. Wang H.-Y., Friedman E. Effects of lithium on receptor-mediated activation of G-proteins in rat brain cortical membranes. Neuropharmacology. 38:1999;403-414.
72. 1A receptors in rat brain following antidepressant drug treatment. Synapse. 4:1989;347-352.